Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
Drug Test Anal. 2020 Nov;12(11-12):1614-1619. doi: 10.1002/dta.2914. Epub 2020 Sep 1.
Early in 2020, racehorse doping cases revolved around the hypoxia-inducible factor (HIF) activator IOX-2. While the composition of IOX-2 has also been known and monitored in human doping controls for several years, the testing capability of routine sports drug testing methods was revisited for this newly surfaced doping agent. IOX-2 and the analytically well-established HIF activator roxadustat (FG-4592) share identical precursor/product ion pairs, enabling their co-detection in existing initial testing procedures in routine doping controls for the intact unconjugated analytes. In addition, hydroxylated IOX-2 and the corresponding glucuronic acid conjugates were identified as major metabolites in a microdose elimination study, contributing to enhanced initial testing and confirmation procedures.
2020 年初，赛马兴奋剂案件集中在低氧诱导因子 (HIF) 激活剂 IOX-2 上。虽然 IOX-2 的成分也已经在人类兴奋剂控制中被了解和监测了多年，但针对这种新出现的兴奋剂，常规运动药物测试方法的测试能力再次受到了审查。IOX-2 和分析上成熟的 HIF 激活剂罗沙司他（FG-4592）具有相同的前体/产物离子对，这使得它们可以在现有的常规兴奋剂控制中用于完整未缀合分析物的初始检测程序中共同检测。此外，在微剂量消除研究中，鉴定出了羟基化的 IOX-2 和相应的葡萄糖醛酸缀合物作为主要代谢物，这有助于增强初始检测和确认程序。
